Safety and immunogenicity of HIV recombinant envelope vaccines in HIV-infected infants and children

AIDS vaccines made from the HIV gp120 or gp 160 protein appear to be safe enough to use in infants and children. Researchers vaccinated 72 HIV-infected children between one month and 18 years old with a gp120 vaccine, a gp160 vaccine, or a placebo approximately every month for about six months. Sixty-five percent of those who received the vaccine developed an immune response to it, which did not occur in the placebo group.